Compared with either anti-IL6R or anti-PD-L1 monotherapy, combined blockade of IL6R and PD-L1 significantly improved tumor control and progression-free survival (HR = 0.11, p < 0.0001; Figures 2A and 2B). This evidence concerns the gene IL6R and neoplasm.